Multiple sclerosis and Dissociative identity disorder

Summary:

Dissociative identity disorder is found among people with Multiple sclerosis, especially for people who are female, 40-49 old.

The study analyzes which people have Dissociative identity disorder with Multiple sclerosis. It is created by eHealthMe based on reports of 12 people who have Multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,089 drugs and 1,358 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

What is Dissociative identity disorder?

Dissociative identity disorder is found to be associated with 37 drugs and 148 conditions by eHealthMe. Check the latest studies of Dissociative identity disorder.

On Jul, 10, 2026

12 people who have Multiple Sclerosis and Dissociative Identity Disorder are studied.

Would you have Dissociative identity disorder when you have Multiple sclerosis?

Gender of people who have Multiple Sclerosis and experienced Dissociative Identity Disorder *:

female: 66.67 %
male: 33.33 %

Age of people who have Multiple Sclerosis and experienced Dissociative Identity Disorder *:

Common co-existing conditions for these people *:

Hypersensitivity: 1 person, 8.33%
Gait Disturbance: 1 person, 8.33%
Dermatitis Allergic (inflammation of the skin due allergic reaction): 1 person, 8.33%

Common drugs taken by these people *:

Tysabri: 5 people, 41.67%
Rebif: 2 people, 16.67%
Zyrtec: 1 person, 8.33%
Lunesta: 1 person, 8.33%
Ampyra: 1 person, 8.33%
Dupixent: 1 person, 8.33%
Fingolimod Hydrochloride: 1 person, 8.33%
Fish Oil: 1 person, 8.33%
Gilenya: 1 person, 8.33%
Lamictal: 1 person, 8.33%

Common symptoms for these people *:

Depression: 2 people, 16.67%
Balance Disorder: 2 people, 16.67%
Post-Traumatic Stress Disorder: 2 people, 16.67%
Swelling: 1 person, 8.33%
Gait Disturbance: 1 person, 8.33%
Feeling Abnormal: 1 person, 8.33%
Fatigue (feeling of tiredness): 1 person, 8.33%
Emotional Disorder: 1 person, 8.33%
Drug Ineffective: 1 person, 8.33%
Dizziness: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Dissociative identity disorder?

- Check whether Dissociative identity disorder is associated with a drug or a condition

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Dissociative identity disorder and Multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.